Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Google DeepMind, Meta, Isomorphic Labs Invest $300 Million in Biohub's Initiative to Build AI Data to Treat Disease

Google DeepMind, Meta, Isomorphic Labs Invest $300 Million in Biohub's Initiative to Build AI Data to Treat Disease

MT newswireMT newswire2026/10/07 14:20

10:20 AM EDT, 10/07/2026 (MT Newswires) -- Alphabet's (GOOGL, GOOG) Google DeepMind, Meta (META), and Isomorphic Labs are collectively investing $300 million in Biohub's Virtual Biology Initiative to build datasets for artificial intelligence models to predict and treat disease, Biohub said Wednesday. The investments will be used to create technologies and multi-modal datasets to enable the global scientific community to build and use AI models, allowing researchers to ask, predict, and answer biological questions digitally, Biohub said. Biohub added that the US Department of Energy will invest more than $500 million over five years in lab measurement, modeling and computation towards the initiative. Additionally, the US National Institutes of Health will coordinate the contribution of relevant datasets, repositories, and knowledge bases developed through over $500 million in prior similar federal initiatives, Biohub said. Price: 344.62, Change: -3.06, Percent Change: -0.88

10:20 AM EDT, 10/07/2026 (MT Newswires) -- Alphabet's (GOOGL, GOOG) Google DeepMind, Meta (META), and Isomorphic Labs are collectively investing $300 million in Biohub's Virtual Biology Initiative to build datasets for artificial intelligence models to predict and treat disease, Biohub said Wednesday. The investments will be used to create technologies and multi-modal datasets to enable the global scientific community to build and use AI models, allowing researchers to ask, predict, and answer biological questions digitally, Biohub said. Biohub added that the US Department of Energy will invest more than $500 million over five years in lab measurement, modeling and computation towards the initiative. Additionally, the US National Institutes of Health will coordinate the contribution of relevant datasets, repositories, and knowledge bases developed through over $500 million in prior similar federal initiatives, Biohub said. Price: 344.62, Change: -3.06, Percent Change: -0.88
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

After Amazon and OpenAI, Synopsys (SNPS.US) also "looks to the East": plans to explore cooperation with Chinese AI laboratories on chip design technology

Global chip design software development leader Synopsys (SNPS.US) plans to explore cooperation with Chinese AI laboratories to improve the chip design process.

智通财经•2026/10/09 02:31

BUZZ - Morningstar expects Woodside's revenue growth will outpace global peers by the end of this decade

On October 9, Morningstar predicted that the revenue of Australian oil and gas producer Woodside Energy (WDS.AX) will grow by over 30% by 2030, outpacing any of its international peers. Woodside Energy’s share price dropped by 0.6% on the day to 32.12 AUD, after surging 2.6% in the previous trading session. The stock is poised to end a three-week losing streak, with oil prices rising due to escalating tensions in the Middle East, and is set for a 2.8% weekly gain O/R. Morningstar expects Woodside’s revenue to increase as major new projects come online, and forecasts free cash flow to exceed 7 billion USD after 2030, reflecting a 300% rise from 2025. The report added that market sentiment remains bearish, with the current share price below its estimated fair value of 44.00 AUD. Year-to-date, Woodside’s share price has risen 36.2%, while Santos shares are up 41.3%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several languages. Since automated translations may be inaccurate or lack required context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for the convenience of readers. Reuters accepts no liability for any loss or damage arising from your use of automated translation functions.)

路透社•2026/10/09 02:16

Star analyst Ives: Bullish on Apple (AAPL.US) up to $400, AI strategy may increase valuation by $75 per share

Ives has given Apple stock an "outperform" rating, with a target price of $400.

智通财经•2026/10/09 02:01